Active Biotech's Novel Cancer Treatment ANYARA Shows Pharmacological Proof of Concept after Successful Phase I Studies


Active Biotech (ACTI.ST) today announced the successful completion of three clinical Phase I studies of ANYARA for the treatment of advanced non-small cell lung cancer (NSCLC), renal cell cancer (RCC) and pancreatic cancer (PC). These studies confirm that ANYARA has now demonstrated pharmacological proof of concept.

Anhänge

Read the complete press release - December 13, 2006
GlobeNewswire